$810.58
1.35% today
NYSE, Dec 03, 05:46 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$799.80
-6.34 0.79% 1M
-31.46 3.78% 6M
+216.88 37.21% YTD
+214.12 36.56% 1Y
+551.92 222.66% 3Y
+683.06 585.11% 5Y
+729.42 1,036.40% 10Y
NYSE, Closing price Mon, Dec 02 2024
+4.45 0.56%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $759.26b
Enterprise Value $786.94b
P/E (TTM) P/E ratio 87.49
EV/FCF (TTM) EV/FCF 562.18
EV/Sales (TTM) EV/Sales 19.26
P/S ratio (TTM) P/S ratio 18.58
P/B ratio (TTM) P/B ratio 53.37
Dividend yield 0.65%
Last dividend (FY24) $5.20
Revenue growth (TTM) Revenue growth 27.41%
Revenue (TTM) Revenue $40.86b
EBIT (operating result TTM) EBIT $14.44b
Free Cash Flow (TTM) Free Cash Flow $1.40b
Cash position $3.52b
EPS (TTM) EPS $9.14
P/E forward 62.94
P/S forward 16.63
EV/Sales forward 17.23
Short interest 0.82%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,876 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Eli Lilly and Company forecast:

24x Buy
80%
5x Hold
17%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a Eli Lilly and Company forecast:

Buy
80%
Hold
17%
Sell
3%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
40,863 40,863
27% 27%
100%
- Direct Costs 7,803 7,803
14% 14%
19%
33,061 33,061
31% 31%
81%
- Selling and Administrative Expenses 6,424 6,424
15% 15%
16%
- Research and Development Expense 10,531 10,531
20% 20%
26%
16,106 16,106
48% 48%
39%
- Depreciation and Amortization 1,670 1,670
10% 10%
4%
EBIT (Operating Income) EBIT 14,436 14,436
54% 54%
35%
Net Profit 8,370 8,370
68% 68%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
WSJ
3 days ago
Data from their most serious competitor, Amgen, suggests the biotech won't upstage the market leaders.
Neutral
Seeking Alpha
5 days ago
Eli Lilly investors have suffered an unexpected bear market as recent headwinds buffeted the stock. Notwithstanding near-term execution challenges, Lilly's weight loss drugs are gaining more share. Potential policy changes under the Biden administration could benefit Lilly, but they are unlikely to be resolved before Trump takes office.
Positive
MarketBeat
5 days ago
Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 43,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today